CN117224424B - Whitening, tightening and repairing freeze-dried powder and preparation method and application thereof - Google Patents
Whitening, tightening and repairing freeze-dried powder and preparation method and application thereof Download PDFInfo
- Publication number
- CN117224424B CN117224424B CN202311158651.9A CN202311158651A CN117224424B CN 117224424 B CN117224424 B CN 117224424B CN 202311158651 A CN202311158651 A CN 202311158651A CN 117224424 B CN117224424 B CN 117224424B
- Authority
- CN
- China
- Prior art keywords
- parts
- freeze
- dried powder
- whitening
- tightening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 68
- 230000002087 whitening effect Effects 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 69
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000008439 repair process Effects 0.000 claims abstract description 21
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910003472 fullerene Inorganic materials 0.000 claims abstract description 19
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 15
- 239000011259 mixed solution Substances 0.000 claims abstract description 14
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims abstract description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 12
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 12
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 12
- 239000001168 astaxanthin Substances 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- 229930195725 Mannitol Natural products 0.000 claims abstract description 10
- 239000000594 mannitol Substances 0.000 claims abstract description 10
- 235000010355 mannitol Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 8
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 230000003712 anti-aging effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 33
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 6
- 229930186217 Glycolipid Natural products 0.000 abstract description 6
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 230000000052 comparative effect Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 24
- 239000000523 sample Substances 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 17
- 108010003272 Hyaluronate lyase Proteins 0.000 description 15
- 102000001974 Hyaluronidases Human genes 0.000 description 15
- 229960002773 hyaluronidase Drugs 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 13
- 239000002245 particle Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036564 melanin content Effects 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- -1 amino hexose Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Cosmetics (AREA)
Abstract
The invention belongs to the technical field of skin care products, and discloses whitening, tightening and repairing freeze-dried powder as well as a preparation method and application thereof. The whitening tightening repair freeze-dried powder comprises the following raw material components in parts by weight: 1-8 parts of astaxanthin; 2-10 parts of vitamin E; 2-15 parts of mannitol; 0.5 to 5 parts of sodium hyaluronate; 51-8 parts of acetyl tetrapeptide; 0.5-5 parts of fullerene; 0.5 to 6 portions of polyquaternium-10; 10-40 parts of glycolipid. The preparation method comprises the following steps: and (3) homogenizing and mixing an ethanol mixed solution containing astaxanthin, vitamin E, glycolipid and fullerene with an aqueous solution containing mannitol, sodium hyaluronate, acetyl tetrapeptide-5 and polyquaternium-10 uniformly, filtering to remove insoluble substances, and performing vacuum freeze drying to obtain the whitening, tightening and repairing freeze-dried powder. The freeze-dried powder disclosed by the invention has good moisturizing and relieving effects and whitening, tightening and repairing effects.
Description
Technical Field
The invention belongs to the technical field of skin care products, and particularly relates to whitening, tightening and repairing freeze-dried powder as well as a preparation method and application thereof.
Background
The freeze-dried powder is a formulation product newly added in the beauty industry in recent years, and is the development and application of biological freeze-drying technology in the beauty industry. The product to be dried is frozen at low temperature, and then dried in vacuum environment to sublimate the water directly from solid state into steam and eliminate the steam from the product, thus actively drying the product. The freeze-dried powder can well maintain the activity of the functional components, and has good protection effect on some substances which are easy to oxidize because the drying is carried out under the vacuum condition. The water content of the product after freeze-drying is very low, so that the stability of the product is improved, the probability of pollution is reduced, the transportation is convenient, and the storage life of the product is prolonged.
Patent CN 108721137A discloses a freeze-dried powder for repairing skin, which comprises the following raw materials in parts by weight: 0.2-0.5 part of pilose antler polypeptide, 5-10 parts of hydroxyproline, 5-10 parts of albumin, 0.5-0.8 part of disodium hydrogen phosphate, 11-3 parts of oligopeptide, 5-8 parts of proline, 3-10 parts of asiaticoside, 20-25 parts of freeze-drying protective agent and 10-15 parts of tween. The formula mainly focuses on the repairing effect, and the components are better matched with the solvent liquid to use, and a large amount of surfactant Tween is adopted, so that the use feeling is not moist and fine enough.
Patent CN 111150676A discloses a freeze-dried powder for deep skin repair, comprising a freeze-dried powder carrier, oligopeptide-5, miRNA-33, algal polysaccharide, arginine, sodium hyaluronate, ceramide 3 and ectoin. The novel freeze-dried powder carrier based on PNIPAM is adopted in the patent, and has high permeability, strong air permeability, strong adsorption effect on solvent and high absorption rate. But the freeze-dried powder carrier is complex to prepare and has higher cost.
Patent CN114533570a discloses a fullerene freeze-dried powder with repairing and anti-aging effects, which is prepared from one or more of the following components in percentage by mass: 0.04 to 0.1 percent of fullerene, 3.0 to 5.0 percent of mannitol, 0.1 to 0.2 percent of trehalose, 0.2 to 0.3 percent of glucose, 0.1 to 1.0 percent of histidine, 0.2 to 1.0 percent of arginine, 0.2 to 1.0 percent of glycine, 0.4 to 0.5 percent of polyglutamic acid, 0.1 to 0.2 percent of hyaluronic acid, 1.0 to 2.0 percent of pullulan polysaccharide, 1.0 to 3.5 percent of hydrolyzed collagen and 90.04 to 91.06 percent of water. The freeze-dried powder plays the roles of resisting oxidation, promoting collagen proliferation, assisting wound healing and the like by adding the fullerene, and the trehalose is used as a protective agent, so that the activity of the fullerene is effectively ensured. However, the freeze-dried powder has poor dissolution and dispersion effects in the solvent, so that the film forming effect and the skin feel of the subsequent use are required to be further improved.
Disclosure of Invention
Aiming at the defects and the shortcomings of the prior art, the primary purpose of the invention is to provide whitening, tightening and repairing freeze-dried powder. The whitening, tightening and repairing freeze-dried powder takes the specific glycolipid component as a carrier and a protective agent of the efficacy active component, and has the efficacy of synergistically improving the moisturizing, repairing and soothing; meanwhile, the specific polyquaternium-10 is adopted as a freeze-dried powder forming auxiliary agent, so that the particle size of the freeze-dried powder can be reduced, the dissolution and dispersion effects of the freeze-dried powder in a solvent are obviously promoted, and the effects of low irritation and good skin feel in use are achieved.
The invention further aims at providing a preparation method of the whitening, tightening and repairing freeze-dried powder.
The invention further aims to provide application of the whitening tightening repair freeze-dried powder in preparation of a multi-effect repair anti-aging composition.
The invention aims at realizing the following technical scheme:
the whitening, tightening and repairing freeze-dried powder comprises the following raw material components in parts by weight:
further preferably, the whitening tightening repair freeze-dried powder comprises the following raw material components in parts by weight:
further, the glycolipid is preferably a glyceroglycolipid.
The preparation method of the whitening, tightening and repairing freeze-dried powder comprises the following preparation steps:
(1) Adding astaxanthin, vitamin E and glycolipid into ethanol for uniform dissolution, adding fullerene, stirring and dispersing uniformly to obtain ethanol mixed solution;
(2) Mannitol, sodium hyaluronate, acetyl tetrapeptide-5 and polyquaternium-10 are added into water to be dissolved uniformly, so as to obtain an aqueous solution;
(3) And (3) homogenizing and mixing the ethanol mixed solution in the step (1) and the aqueous solution in the step (2), filtering to remove insoluble substances, and performing vacuum freeze drying to obtain the whitening compact repairing freeze-dried powder.
Further, the dissolving and stirring operation in the step (1) is performed at 20-70 ℃.
Further, the dissolving operation in the step (2) is performed at 20 to 80 ℃.
Further, in the mixing process of the ethanol mixed solution and the aqueous solution in the step (3), the mass ratio of ethanol to water is required to be kept within the range of 1-3:1. The freeze-dried powder obtained by freeze drying under the condition of the solvent proportion has fine particle size and good dissolving and dispersing effects in the solvent.
The application of the whitening tightening repair freeze-dried powder in preparing a multi-effect repair anti-aging composition.
Further, the application method comprises the following steps: and mixing, dissolving and dispersing the whitening tightening repair freeze-dried powder and the solvent liquid uniformly to obtain the multi-effect repair anti-aging composition.
Compared with the prior art, the invention has the beneficial effects that:
(1) The freeze-dried powder disclosed by the invention adopts astaxanthin with the functions of resisting oxygen, whitening and moistening, vitamin E component, anti-aging and repairing sodium hyaluronate, acetyl tetrapeptide-5 component and fullerene component with the functions of resisting oxygen, whitening and resisting aging, and the whitening, tightening and repairing effects of the freeze-dried powder are obviously improved through the synergistic effect of the components.
(2) The carrier and the protective agent which take the specific glycolipid component as the effective active component have better synergistic effect of improving the moisturizing, repairing and relieving effects compared with other carriers such as trehalose and the like. Has obvious effect of stabilizing active ingredients.
(3) The invention adopts the specific polyquaternium-10 as the forming auxiliary agent of the freeze-dried powder, can reduce the particle size of the freeze-dried powder and obviously promote the dissolution and dispersion effects of the freeze-dried powder in aqueous solvent, and has the effects of low irritation and good skin feel in use.
(4) The preparation method of the freeze-dried powder can reduce the particle size of the freeze-dried powder and promote the dissolution and dispersion effects of the freeze-dried powder in solvent liquid by controlling the ratio of ethanol to water in the solvent.
Detailed Description
The present invention will be described in further detail with reference to examples, but embodiments of the present invention are not limited thereto.
Example 1
The whitening, tightening and repairing freeze-dried powder comprises the following raw material components in parts by weight:
the preparation method of the whitening tightening repair freeze-dried powder comprises the following steps:
(1) According to the parts by weight, adding astaxanthin, vitamin E and glyceroglycolipid into 100 parts by weight of ethanol with the temperature of 50 ℃ for uniform dissolution, adding fullerene, and stirring and dispersing uniformly to obtain ethanol mixed solution.
(2) Mannitol, sodium hyaluronate, acetyl tetrapeptide-5 and polyquaternium-10 are added into 50 parts by weight of water with the temperature of 60 ℃ for uniform dissolution, and an aqueous solution is obtained.
(3) And (3) homogenizing and mixing the ethanol mixed solution in the step (1) and the aqueous solution in the step (2), filtering to remove insoluble substances, and performing vacuum freeze drying to obtain the whitening compact repairing freeze-dried powder.
Example 2
The whitening, tightening and repairing freeze-dried powder comprises the following raw material components in parts by weight:
the preparation method of the whitening tightening repair freeze-dried powder comprises the following steps:
(1) According to the mass parts, astaxanthin, vitamin E and glyceroglycolipid are added into 80 parts by weight of ethanol with the temperature of 60 ℃ to be dissolved uniformly, then fullerene is added into the mixture to be stirred and dispersed uniformly, and the ethanol mixed solution is obtained.
(2) Mannitol, sodium hyaluronate, acetyl tetrapeptide-5 and polyquaternium-10 are added into 40 parts by weight of 70 ℃ water to be dissolved uniformly, so as to obtain an aqueous solution.
(3) And (3) homogenizing and mixing the ethanol mixed solution in the step (1) and the aqueous solution in the step (2), filtering to remove insoluble substances, and performing vacuum freeze drying to obtain the whitening compact repairing freeze-dried powder.
Example 3
The whitening, tightening and repairing freeze-dried powder comprises the following raw material components in parts by weight:
the preparation method of the whitening tightening repair freeze-dried powder comprises the following steps:
(1) According to the parts by weight, adding astaxanthin, vitamin E and glyceroglycolipid into 120 parts by weight of ethanol with the temperature of 45 ℃ for uniform dissolution, adding fullerene, and stirring and dispersing uniformly to obtain ethanol mixed solution.
(2) Mannitol, sodium hyaluronate, acetyl tetrapeptide-5 and polyquaternium-10 are added into 60 parts by weight of water with the temperature of 60 ℃ for uniform dissolution, and an aqueous solution is obtained.
(3) And (3) homogenizing and mixing the ethanol mixed solution in the step (1) and the aqueous solution in the step (2), filtering to remove insoluble substances, and performing vacuum freeze drying to obtain the whitening compact repairing freeze-dried powder.
Comparative example 1
In this comparative example, no glyceroglycolipid was added and the remaining components were the same as in example 1.
Comparative example 2
This comparative example uses the same amount of trehalose instead of the glyceroglycolipid as in example 1, and the remaining components are the same.
Comparative example 3
In this comparative example, astaxanthin and vitamin E were not added and the remaining components were the same as in example 1.
Comparative example 4
In this comparative example, sodium hyaluronate and acetyl tetrapeptide-5 were not added and the remaining components were the same as in example 1.
Comparative example 5
In this comparative example, compared with example 1, no fullerene was added, and the remaining components were the same.
The application performance test is carried out on the freeze-dried powder obtained in the above examples and comparative examples:
the freeze-dried powder and a basic solvent solution (composed of 93.8% of water, 3.5% of glycerol, 2.5% of butanediol and 0.2% of disodium hydrogen phosphate) are mixed according to the proportion of 100mg to 5mL, and the mixture is uniformly mixed and dissolved by a shaking table to be used as a test sample.
1. Moisture effect test
The testing method comprises the following steps:
under constant environmental conditions, a negative control group and a positive control group were set, the positive control group was 5% glycerol, the negative control group was deionized water, and the operation procedure was consistent with that of the sample group.
1. Placing color-changing silica gel at the bottom of the dryer, attaching 3M air-permeable adhesive tape onto glass plate, placing into the dryer one day in advance, and weighing M 0 ；
2. Accurately weighing sample, weighing corresponding sample and reference substance according to the size of the adhesive tape at a ratio of 2mg + -0.1 mg/cm2, uniformly coating on the adhesive tape, and weighing the weight M 1 ；
3. Placing the glass plate coated with the object to be measured into a dryer, and accurately weighing the mass M after 2 hours, 4 hours and 6 hours t ；
4. The formula for calculating the moisture retention (P) refers to the following formula:
moisture retention (%) = (M t –M 0 )/(M 1 –M 0 )×100％；
5. Relative moisture retention: comparison of the moisture retention properties of the test samples with 5% glycerol under the same conditions;
6. the relative moisture retention calculation formula is referred to below
Relative moisture retention (%) = (P) t –P 0 )/(P Glycerol –P 0 )×100％；
Wherein: pt-the moisture retention rate of the sample to be measured after t hours;
p0-moisture retention after t hours for negative control;
P glycerol -yangMoisture retention% of sex control after t hours.
The relative moisture retention rate evaluation results of the above examples and comparative examples are shown in table 1 below.
TABLE 1
The relative moisture retention rate is lower than 0-50%, 50-100% is middle, 100-150% is high, and 150% is good. Through tests, the relative moisture retention rates of the sample solution in the embodiment of the invention at 2h, 4h and 6h are all over 100%, and the moisture retention performance is high. Wherein the moisturizing performance of comparative example 1 is significantly reduced without adding glyceroglycolipid. Meanwhile, as can be seen from the result of comparative example 2, the use of glyceroglycolipid as a carrier in the system of the present invention has significantly improved moisturizing properties compared to trehalose. As can be seen from the results of comparative examples 3 to 5, the other functional components have relatively little effect on the moisturizing performance.
2. Test of soothing efficacy
The current study considers the occurrence of sensitive skin as a complex process involving skin barrier-neurovascular-immune inflammation. Hyaluronic acid is the component with the largest content and proportion in the extracellular matrix, can maintain the volume of the extracellular matrix, regulate and control the secretion of cell growth factors and cytokines, and influence the adhesion, growth, proliferation and differentiation of cells, thereby playing an important role in maintaining the skin moisture and elasticity, wound healing, angiogenesis and other processes.
Hyaluronidase is an endogenous amino hexose which causes the decomposition of macromolecular hyaluronic acid, has strong correlation with inflammation and allergy, and researches report that various medicines for releasing histamine by fat large cells can regulate the activity of the hyaluronidase, and some antiallergic medicines have strong inhibition of the activity of the hyaluronidase, so that the inhibition of the activity of the hyaluronidase is used as an index for researching the antiallergic effect.
The macromolecular hyaluronic acid is decomposed to generate the N-acetylglucosamine under the action of hyaluronidase, and the activity of the hyaluronidase can be indirectly reacted by measuring the N-acetylglucosamine content in a reaction system. The inhibition of the activity of the hyaluronidase can ensure the normal content and function of the hyaluronic acid, so that whether a test sample has the effect of relieving or not can be judged by utilizing the inhibition rate of the hyaluronidase activity, and the higher the inhibition rate of the hyaluronidase activity is, the stronger the relieving effect of the substance is reflected, and the weaker the relieving effect is on the contrary.
The testing method comprises the following steps:
and (3) taking a proper amount of sample and a solution of hyaluronidase and the like for color reaction, testing absorbance at 530nm, and calculating the inhibition rate (%) of the hyaluronidase activity.
Hyaluronidase inhibition ratio (%) = [ (C-D) - (a-B) ]/(C-D) ×100%;
wherein: OD value of a- (hyaluronidase + sample + potassium hyaluronate) sample solution;
OD value of B- (hyaluronidase + sample + acetate buffer) sample blank;
OD value of C- (hyaluronidase + deionized water + potassium hyaluronate) control solution;
d- (acetate buffer + deionized water + acetate buffer) versus OD value of blank.
The results of the soothing efficacy evaluation of the above examples and comparative examples are shown in Table 2 below.
TABLE 2
The results in Table 2 show that the glyceroglycolipid, sodium hyaluronate and acetyl tetrapeptide-5 and fullerene components of the invention have obvious synergistic effect on the exertion effect of the lyophilized powder.
3. Whitening efficacy test
The testing method comprises the following steps: the 40 volunteers with darker complexion were screened and randomly divided into 8 groups of 5 volunteers. The skin red melanin tester and test probe (Mexameter MX18, CK, germany) were used to collect melanin MI data from the face prior to sample testing, and the data were used as skin background values. The sample was used once in the morning and evening by the test person, and data were collected after 4 weeks of continuous use. The change of the melanin content of the skin of the subject before and after the sample is tested is evaluated, so that the whitening effect is determined. The corresponding test results are shown in table 3 below.
Wherein, the melanin content change rate Δmi% = (T n -T 0 )/T 0 Averaging the final result; the higher Δmi% reduction value indicates better whitening efficacy.
Wherein T is n -the melanin content value of the tested area after 4 weeks of continuous use; t (T) 0 -initial value of melanin content of the test area.
TABLE 3 Table 3
The results in Table 3 show that the glyceroglycolipid, astaxanthin, vitamin E and fullerene have obvious synergistic effect on the whitening effect of the freeze-dried powder.
4. Skin elasticity test
The testing method comprises the following steps: female volunteers 40 persons aged 25-40 years were selected and randomized into 8 groups of 5 persons each. A fixed area with the size of 2cm multiplied by 2cm is selected on the arm of a subject, 0.5g of a sample to be measured is smeared every day, and the smearing is carried out for two weeks. The skin elasticity of the test skin was measured by using the skin elasticity tester MPA580 of German CK company, and the average value of R2 (R2 value means the ratio of the rebound quantity of the skin without negative pressure to the maximum stretching quantity with negative pressure) was recorded, and the closer the ratio to 1, the better the skin elasticity was. The results are shown in Table 4 below.
TABLE 4 Table 4
| Test sample | R2 value |
| Example 1 | 0.94 |
| Example 2 | 0.92 |
| Example 3 | 0.92 |
| Comparative example 1 | 0.79 |
| Comparative example 2 | 0.82 |
| Comparative example 3 | 0.86 |
| Comparative example 4 | 0.73 |
| Comparative example 5 | 0.76 |
As apparent from the results in Table 4, the glyceroglycolipid of the present invention has a remarkable synergistic effect with sodium hyaluronate and acetyl tetrapeptide-5, and the fullerene component in the effect of the elastic compaction of the lyophilized powder.
5. Test of repair and anti-aging effects
The test method employs a method of promoting human skin fibroblast proliferation (MTT assay):
taking human skin fibroblast in logarithmic growth phase, digesting, preparing into 1×10 concentration with DMEM medium containing 15% fetal calf serum and 1% diabody 5 Cell suspension/mL, inoculated in 96-well plate at 150. Mu.L per well, 37℃and 5% CO 2 After culturing in an incubator for 24 hours, the culture medium is replaced by DMEM culture medium containing 50 mug/mL of sample to be tested, 15% fetal bovine serum and 1% double antibody for continuous culture, after continuous culture for 24 hours, the culture medium is sucked, PBS is used for washing, 150 mug of DMEM culture medium containing 15% fetal bovine serum and 1% double antibody and 20 mug LMTT solution (5 mg/mL) are added, 37 ℃ and 5% CO are added 2 Culturing for 4h, absorbing supernatant, adding 150 μl of DMSO into each well, shaking for 10min, and dissolving the crystals completely. Meanwhile, a control group is arranged, wherein the control group is to replace a sample to be tested with normal saline, and the rest is identical, and each group has 5 compound holes. Absorbance was measured at 490nm for each well, 5 sets of experiments were performed for each set, averaged, and proliferation rate calculated. Proliferation rate (%) = (absorbance value of sample to be measured-absorbance value of control group)/(absorbance value of control group×100%, the result is shown in table 5 below.
TABLE 5
| Test sample | Proliferation promoting rate |
| Example 1 | 127.8％ |
| Example 2 | 123.5％ |
| Example 3 | 122.6％ |
| Comparative example 1 | 87.8％ |
| Comparative example 2 | 99.4％ |
| Comparative example 3 | 102.6％ |
| Comparative example 4 | 76.7％ |
| Comparative example 5 | 82.4％ |
The results in Table 5 show that the glyceroglycolipid, sodium hyaluronate, acetyl tetrapeptide-5 and fullerene have obvious synergistic effect on the repairing and anti-aging effects of the freeze-dried powder.
Comparative example 6
Compared with the example 1, the preparation process of the whitening tightening repair freeze-dried powder is not added with polyquaternium-10, and the rest is the same.
The lyophilized powders obtained in example 1 and this comparative example were each tested for the average particle size and dissolution time (mixing at a ratio of 100mg:5ml, shaking table mixing to a time of complete dissolution and dispersion uniformity) in a base solvent (composed of 93.8% by mass of water, 3.5% by mass of glycerin, 2.5% by mass of butylene glycol and 0.2% by mass of disodium hydrogen phosphate) as shown in table 6 below.
TABLE 6
| Test sample | Average particle diameter | Dissolution time |
| Example 1 | 158.6nm | 40s |
| Comparative example 6 | 652.7nm | 2min12s |
As can be seen from the results of Table 6, the invention adopts the specific polyquaternium-10 as the forming auxiliary agent of the freeze-dried powder, which can reduce the particle size of the freeze-dried powder and obviously promote the dissolution and dispersion of the freeze-dried powder in the aqueous solvent.
Example 4
Compared with the embodiment 1, in the preparation process of the whitening tightening repair freeze-dried powder, the mass ratio of the ethanol to the water in the mixed liquid solvent before vacuum freeze-drying is respectively regulated to be 0.5:1, 1:1, 2:1, 3:1 and 4:1, and the total addition amount of the ethanol and the water is 150 parts by weight and is kept unchanged. The average particle diameter and dissolution time in the base solvent were measured for the obtained lyophilized powder, respectively, and the results are shown in table 7 below.
TABLE 7
| Test sample | Average particle diameter | Dissolution time |
| 0.5:1 | 465.4nm | 1min32s |
| 1:1 | 245.3nm | 52s |
| 2:1 | 158.6nm | 40s |
| 3:1 | 212.7nm | 48s |
| 4:1 | 328.2nm | 1min6s |
As can be seen from the results in table 7, as the mass ratio of ethanol to water in the mixed solution solvent before freeze-drying increases, the particle size of the obtained freeze-dried powder tends to decrease and then increase, and the smaller the particle size, the shorter the dissolution time. Under the condition that the mass ratio of the ethanol to the water is 1-3:1, the dissolution and dispersion time of the obtained freeze-dried powder can be controlled within 1 min.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (8)
1. The whitening, tightening and repairing freeze-dried powder is characterized by comprising the following raw material components in parts by weight:
1-8 parts of astaxanthin;
2-10 parts of vitamin E;
2-15 parts of mannitol;
0.5-5 parts of sodium hyaluronate;
acetyl tetrapeptide-5-8 parts;
0.5-5 parts of fullerene;
0.5-6 parts of polyquaternium-10;
10-40 parts of glyceroglycolipid.
2. The whitening and tightening repair freeze-dried powder according to claim 1, which is characterized by comprising the following raw material components in parts by weight:
2-6 parts of astaxanthin;
4-8 parts of vitamin E;
5-10 parts of mannitol;
1-3 parts of sodium hyaluronate;
3-6 parts of acetyl tetrapeptide-5;
2-4 parts of fullerene;
2-5 parts of polyquaternium-10;
15-30 parts of glyceroglycolipid.
3. The preparation method of the whitening tightening repair freeze-dried powder as claimed in claim 1 or 2, which is characterized by comprising the following preparation steps:
(1) Adding astaxanthin, vitamin E and glyceroglycolipid into ethanol, dissolving uniformly, adding fullerene, stirring and dispersing uniformly to obtain ethanol mixed solution;
(2) Mannitol, sodium hyaluronate, acetyl tetrapeptide-5 and polyquaternium-10 are added into water to be dissolved uniformly, so as to obtain an aqueous solution;
(3) And (3) homogenizing and mixing the ethanol mixed solution in the step (1) and the aqueous solution in the step (2), filtering to remove insoluble substances, and performing vacuum freeze drying to obtain the whitening compact repairing freeze-dried powder.
4. The method for preparing the whitening, tightening and repairing freeze-dried powder according to claim 3, wherein the dissolving and stirring operation in the step (1) is performed at 20-70 ℃.
5. The method for preparing the whitening, tightening and repairing freeze-dried powder according to claim 3, wherein the dissolving operation in the step (2) is performed at 20-80 ℃.
6. The method for preparing the whitening, tightening and repairing freeze-dried powder according to claim 3, wherein in the mixing process of the ethanol mixed solution and the aqueous solution in the step (3), the mass ratio of ethanol to water is kept within a range of 1-3:1.
7. Use of a lyophilized powder for whitening and tightening repair according to claim 1 or 2 for preparing a repair anti-aging composition.
8. The application of the whitening tightening repair freeze-dried powder in preparing repair anti-aging compositions according to claim 7, wherein the application method is as follows: and mixing, dissolving and dispersing the whitening, tightening and repairing freeze-dried powder and the solvent liquid uniformly to obtain the repairing and anti-aging composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311158651.9A CN117224424B (en) | 2023-09-08 | 2023-09-08 | Whitening, tightening and repairing freeze-dried powder and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311158651.9A CN117224424B (en) | 2023-09-08 | 2023-09-08 | Whitening, tightening and repairing freeze-dried powder and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117224424A CN117224424A (en) | 2023-12-15 |
| CN117224424B true CN117224424B (en) | 2024-03-08 |
Family
ID=89090466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311158651.9A Active CN117224424B (en) | 2023-09-08 | 2023-09-08 | Whitening, tightening and repairing freeze-dried powder and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117224424B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0834746A (en) * | 1994-07-25 | 1996-02-06 | Kanagawa Kagaku Gijutsu Akad | Medicinal carrier comprising sphingoglycolipid micelle |
| JP2002293712A (en) * | 2001-03-29 | 2002-10-09 | Mercian Corp | Cosmetic |
| EP2347755A2 (en) * | 2009-03-20 | 2011-07-27 | ROVI Cosmetics International GmbH | Cosmetic compound with active ingredients for reducing wrinkles and/or reducing the depth of pores |
| CN110237022A (en) * | 2019-07-03 | 2019-09-17 | 斯微(上海) 生物科技有限公司 | A kind of freeze-dried powder, solvent and its application |
| CN111166683A (en) * | 2019-12-28 | 2020-05-19 | 嘉汶化妆品(东莞)有限公司 | Fullerene anti-aging antioxidant beauty and skin care cosmetic and preparation method thereof |
-
2023
- 2023-09-08 CN CN202311158651.9A patent/CN117224424B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0834746A (en) * | 1994-07-25 | 1996-02-06 | Kanagawa Kagaku Gijutsu Akad | Medicinal carrier comprising sphingoglycolipid micelle |
| JP2002293712A (en) * | 2001-03-29 | 2002-10-09 | Mercian Corp | Cosmetic |
| EP2347755A2 (en) * | 2009-03-20 | 2011-07-27 | ROVI Cosmetics International GmbH | Cosmetic compound with active ingredients for reducing wrinkles and/or reducing the depth of pores |
| CN110237022A (en) * | 2019-07-03 | 2019-09-17 | 斯微(上海) 生物科技有限公司 | A kind of freeze-dried powder, solvent and its application |
| CN111166683A (en) * | 2019-12-28 | 2020-05-19 | 嘉汶化妆品(东莞)有限公司 | Fullerene anti-aging antioxidant beauty and skin care cosmetic and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117224424A (en) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsumoto et al. | Development of a wound dressing composed of hyaluronic acid sponge containing arginine and epidermal growth factor | |
| CN112043621B (en) | Preservative-free polypeptide composition with anti-aging effect | |
| CN109846743B (en) | Moisturizing and repairing composition and preparation method and application thereof | |
| KR101895038B1 (en) | Dissolvable film comprising spicule and use thereof | |
| CN113842334A (en) | Composition for promoting skin multi-dimensional defense and repair and preparation method thereof | |
| CN104887542B (en) | A cosmetic composition | |
| CN111228134A (en) | Snake venom peptide active freeze-dried powder and preparation method thereof | |
| KR20200078433A (en) | Cosmetic composition for anti-wrinkle and whitening containing various growth factor and peptide | |
| CN107596379B (en) | MMP-8 responsive intelligent periodontal drug controlled-release hydrogel material and application thereof | |
| CN117224424B (en) | Whitening, tightening and repairing freeze-dried powder and preparation method and application thereof | |
| CN116509755B (en) | Inferior throwing separation type mask and mask essence containing same | |
| CN111671695B (en) | Skin repairing emulsion and application thereof in skin repairing and wrinkle resisting | |
| CN111568781A (en) | Skin care gel and preparation method thereof | |
| CN109077973B (en) | Two-agent carbonic acid foaming mask and preparation method and use method thereof | |
| CN109966170B (en) | Flexible liposome cosmetic containing biological macromolecules and preparation method thereof | |
| CN111358748A (en) | Mask essence containing date palm seed extract and preparation method thereof | |
| CN111135136A (en) | Anti-aging skin care composition and preparation method thereof | |
| EP1949889A1 (en) | Fibroblast activator, method for activation of fibroblast, collagen synthesis promoter, method for promotion of collagen synthesis, skin aging-preventing agent, and method for prevention of aging of the skin | |
| CN111012694A (en) | Hyaluronic acid-containing spray for repairing and moisturizing soles and preparation method thereof | |
| CN117017833B (en) | Compound with multiple-effect repairing and anti-aging effects and preparation method thereof | |
| CN114712269A (en) | Anti-aging essential oil composition and preparation method and application thereof | |
| CN113813219A (en) | Water acupuncture essence containing stem cell repair factors and preparation method thereof | |
| CN115105424B (en) | Anti-wrinkle firming activator for skin care and preparation method thereof | |
| CN112569345A (en) | Dispersion containing growth factor and preparation method and application thereof | |
| CN109864899A (en) | A kind of peptides composition with delay skin aging and preparation method thereof, application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |